Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Adrenergic Receptor
    (1)
  • GSK-3
    (1)
  • GluR
    (1)
  • Histamine Receptor
    (1)
  • Others
    (3)
Filter
Search Result
Results for "

attention deficit hyperactivity disorder (ADHD)

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    9
    TargetMol | Inhibitors_Agonists
  • Isotope Products
    1
    TargetMol | Isotope_Products
Bavisant
JNJ-31001074
TQ0046929622-08-2In house
Bavisant (JNJ-31001074) is a selective and orally active Human H3 receptor antagonist. Bavisant can be used in research on mechanisms of action, involving wakefulness and cognition and the treatment for ADHD.
  • Inquiry Price
6-8 weeks
Size
QTY
Guanfacine hydrochloride
Intuniv hcl, Tenex hcl
T215029110-48-3
Guanfacine hydrochloride (Intuniv) is a centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
CX717
T60201867276-98-0
CX 717 is a positive allosteric modulator of the AMPA receptor with antidepressant-like effects and potential use in adult attention deficit hyperactivity disorder (ADHD) research [1] [2].
  • Inquiry Price
7-10 days
Size
QTY
TargetMol | Inhibitor Sale
Sofiniclin
ABT 894
T10226799279-80-4
Sofiniclin (ABT 894) is an agonist of nicotinic acetylcholine receptor (nAChR). It is used for the research for attention-deficit hyperactivity disorder (ADHD).
  • Inquiry Price
6-8 weeks
Size
QTY
GSK3-IN-9
T205647748145-12-2
GSK3-IN-9 (0713) is a selective inhibitor of glycogen synthase kinase 3 (GSK3). It holds potential for research into fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood epilepsy, intellectual disabilities, diabetes, acute myeloid leukemia (AML), autism, and mental disorders.
  • Inquiry Price
10-14 weeks
Size
QTY
Edivoxetine
LY-2216684,LY 2216684,LY2216684
T316041194508-25-2
Edivoxetine( LY2216684) is a selective norepinephrine reuptake inhibitor being developed as a treatment for attention deficit hyperactivity disorder (ADHD) and antidepressants.
  • Inquiry Price
6-8 weeks
Size
QTY
Guanfacine-13C,15N3
Guanfacine-13C,15N3
T355911189924-28-4
Guanfacine-13C,15N3is intended for us as an internal standard for the quantification of guanfacine by GC- or LC-MS. Guanfacine is an α2-adrenergic receptor (α2-AR) agonist with Kivalues of 93, 1,380, and 3,890 nM for α2A-, α2B-, and α2C-ARs, respectively, in a radioligand binding assay.1It has EC50values of 52, 288, and 602 nM for α2A-, α2B-, and α2C-ARs, respectively, for stimulated [35S]GTPγS binding. It also binds to imidazoline receptor 1 (Ki= 19 nM in a radioligand binding assay).2Guanfacine (0.3-5 mg/kg) binds to adrenergic receptors in the central nervous system and lowers blood pressure in hypertensive rats in a dose-dependent manner.3It also improves spatial working memory deficits induced by hypobaric hypoxia in rats.4Formulations containing guanfacine are used in the treatment of high blood pressure and attention deficit hyperactivity disorder (ADHD). 1.Jasper, J.R., Lesnick, J.D., Chang, L.K., et al.Ligand efficacy and potency at recombinant α2 adrenergic receptors: Agonist-mediated [35S]GTPγS bindingBiochem. Pharmacol.55(7)1035-1043(1998) 2.Nikolic, K., Filipic, S., and Agbaba, D.QSAR study of imidazoline antihypertensive drugsBioorg. Med. Chem.16(15)7134-7140(2008) 3.Scholtysik, G.Pharmacology of guanfacineBr. J. Clin. Pharmacol.10(Suppl 1)21S-24S(1980) 4.Kauser, H., Sahu, S., Kumar, S., et al.Guanfacine is an effective countermeasure for hypobaric hypoxia-induced cognitive declineNeuroscience254110-119(2013)
  • Inquiry Price
Size
QTY
Droxidopa hydrochloride
T603691260173-94-1
Droxidopa (L-DOPS) hydrochloride is a potent, orally active precursor to norepinephrine that elevates standing blood pressure, mitigates orthostatic hypotension symptoms, and enhances standing capability. It holds promise for research in neurogenic orthostatic hypotension (nOH) and alternative attention deficit hyperactivity disorder (ADHD) treatments [1] [2] [3] [4].
  • Inquiry Price
1-2 weeks
Size
QTY
Sofinicline benzenesulfonate
ABT 894 benzenesulfonate
T88302876170-44-4
Sofinicline benzenesulfonate (ABT 894 benzenesulfonate), a novel agonist of the nicotinic acetylcholine receptor, specifically targets the α4β2 subtype of nAChR (IC 50 =0.1 nM). This compound shows promise in enhancing cognitive functions such as attention, memory, and working memory. It is potentially useful in research pertaining to attention deficit hyperactivity disorder (ADHD).
  • Inquiry Price
10-14 weeks
Size
QTY